# Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

> **NCT02103062** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 41 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** ABI-007

## Key facts

- **NCT ID:** NCT02103062
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-05
- **Primary completion:** 2014-11-10
- **Final completion:** 2015-01-09
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02103062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02103062, "Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02103062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*